Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs

Martel-Pelletier, J
Lajeunesse, D
Reboul, P
Pelletier, J-P

Osteoarthritis Research Unit, Centre hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montréal, Québec H2L 4M1 Canada

Correspondence to: Professor J Martel-Pelletier, Osteoarthritis Research Unit, CHUM, Hôpital Notre-Dame, 1560 rue Sherbrooke Est, Pavillon deSève, Montréal (Québec) H2L 4M1, Canada; [email protected]

Accepted 22 November 2002

Annals of the Rheumatic Diseases 62(6):p 501-509, June 2003.

Dual 5-LOX/COX inhibitors are potential new drugs to treat inflammation. They act by blocking the formation of both prostaglandins and leucotrienes but do not affect lipoxin formation. Such combined inhibition avoids some of the disadvantages of selective COX-2 inhibitors and spares the gatrointestinal mucosa.